Biomarin's hemophilia drug meets all endpoints in phase III study

Biomarin has released results from a phase III trial of gene therapy valoctocogene roxaparvovec against severe hemophilia A.

On Sunday, Biotech company Biomarin publicized results from the largest study of a gene therapy hemophilia A treatment ever, at least according to the company itself.

A total of 134 patients have participated in the late-stage trial with the drug candidate valoctocogene roxaparvovec, which was rejected by the US Food and Drug Administration in August 2020 and is currently being evaluated by the European Medicines Agency (EMA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs